WILEX AG

 

 

ENGLISH DEUTSCH

Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.

 

Latest News

06.02.2017: Adhoc-release: WILEX AG secures financing commitment from its main shareholder dievini. WILEX AG today announced that it had secured a further financing commitment from its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany....More

 

 

 

 

Seite gelesen: 34306 | Heute: 150